Introduction

Type 1 diabetes is an insulin-dependent, autoimmune disorder characterized by the destruction of insulin-producing beta cells [1]. Current therapeutic options for individuals with type 1 diabetes include insulin replacement therapy, whole pancreas transplantation, and islet cell transplantation. With insulin replacement therapy, it is nearly impossible to achieve euglycemia consistently, resulting in aberrantly fluctuating blood glucose levels that can lead to acute and long-term complications. Pancreas transplantation often establishes an exogenous insulin-free euglycemic state, reduces long-term complications and improves neural and vascular function [2-5]. Major drawbacks of this procedure include the limited number of human pancreases available for transplantation as well as the requirement for immunosuppressive drugs following transplantation, which may cause alterations in glucose homeostasis and beta cell function [6]. Islet cell transplantation, like whole pancreas transplantation, provides the possibility for internal glycemic control and independence of exogenous insulin [7]; however, this approach is also hampered by a lack of tissue availability and immunological rejection. One theoretical alternative for islet transplantation would involve the use of a renewable source of stem cells capable of self-renewal and differentiation, as well as glucose regulated insulin production. Therefore, the development of a simple, reliable procedure to obtain autologous stem cells capable of differentiation into functional insulin-producing cells (IPC) would...
Insulin-producing cells from bone marrow-derived stem cells

provide a potentially unlimited source of islet cells for transplantation and alleviate the major limitations of availability and allogeneic rejection.

Recent studies have shown that bone marrow-derived stem (BMDS) cells have the ability to be induced to differentiate into a number of neuroectodermal, endothelial, mesenchymal, epithelial, and endodermal cell types [8-14]. Several recent in vivo studies exploring the feasibility of bone marrow-derived cells to differentiate into beta-cells in pancreas have come to different conclusions [15-18], a situation likely resulting from various systems and differentiating conditions. We and other investigators have recently demonstrated that rodent BMDS cells could be induced under high-glucose culture conditions in vitro to become competent insulin-producing cells capable of reducing hyperglycemia in diabetic mice [19, 20]. These findings raised the important question of whether hBMDS cells could also be induced to do the same.

To address this, we hypothesized that hBMDS cells could be induced in vitro to differentiate into functional pancreatic islet-like IPC. In this study, we tested this hypothesis in three steps. First, we derived an hBMDS cell line after long-term in vitro culture, isolated a single cell-derived cell clone, and characterized this cloned cell line. Second, we induced the cloned hBMDS cells undergoing the transdifferentiation to form IPC utilizing culture conditions containing high-glucose and beta-cell maturation factors, followed by confirmation for the presence of insulin and C-peptide production. Third, we tested the functionality of these differentiated (D)-hBMDS cells by their responsiveness to glucose challenge in terms of insulin release, in both in vitro and in vivo settings. Taken together, our results indicate that hBMDS cells can be induced in vitro to differentiate into competent IPC under suitable culture conditions.

Materials and methods

Bone marrow (BM)

Bone marrow was obtained from 10 healthy donors (age two to 30 years) according to guidelines from the University of Florida Institutional Review Board. Human BM mononuclear cells were obtained by Ficoll-Plaque density gradient centrifugation (Sigma Chemical, St. Louis, MO) to remove mature leukocytes and red blood cells.

Cell line culture

The rat INS-1 cell line (clone 832/13) was a generous gift from Dr. Christopher Newgard (Duke University). This cell line was derived from stable transfection of a plasmid containing the human proinsulin gene and expresses and processes both rat and human insulin in response to glucose stimulation. The cells were maintained in RPMI 1640 medium with 11.1 mM D-glucose supplemented with 10% fetal bovine serum [21].

Antibodies

Antibodies against CD45, CD34, CD117, CD38, CD64, CD14, CD13, CD33, CD11b, CD56, CD44, CD90, CD49b, CD19, CD20, CD2, CD5, CD4, CD8, CD3, CD7, HLA-DR, Class I HLA, and β2 microglobulin were from Becton Dickinson Biosciences (San Jose, CA). Rabbit anti-insulin polyclonal IgG (Santa Cruz Biotechnology, Santa Cruz, CA) for immunogold study, polyclonal guinea pig anti-insulin (DAKO Corporation, Carpinteria, CA), rabbit anti-rat-C-peptide antibody (LINCO Research, St. Charles, MO), anti-rabbit IgG and Guinea pig serum, Cy3-coupled anti-guinea pig IgG (DAKO) were utilized for immunocytochemistry.

Serum and cytokines

Culture reagents included fibroblast growth factor (FGF; Sigma, St. Louis, MO), epidermal growth factor (EGF; Peprotech, Rocky Hill, NJ), hepatocyte growth factor (HGF; Peprotech), vascular endothelial growth factor (VEGF; Peprotech), nicotinamide (10 mM; Sigma) and exendin 4 (10 nM; Sigma) and fetal calf serum (FCS; HyClone, Logan, Utah.).

Culture of hBMDS cells

The human BM mononuclear cells were plated in RPMI 1640 plus 20% FCS for 24 to 48 hours (37°C/5% CO2). Unattached cells were removed by washing twice, with adherent cells grown in the same medium until 70 to 80% confluence before passage. Following three to four passages, hBMDS cells became morphologically homogeneous. At this stage, single cell-derived
hBMDS cell lines were cloned by using a cloning cylinder (Fisher Scientific, Pittsburgh, PA), with the selected cells expanded and used for immunophenotypic characterization and for in vitro differentiation. The studies of the in vitro differentiation and characterization of the D-hBMDS cells utilized a single cell-derived clone from bone marrow of a 10-year-old donor without diabetes and hematological disorders. This cell line demonstrated the capacity for unlimited in vitro expansion without showing senescence.

**Flow cytometric analysis**

Approximately $3 \times 10^5$ undifferentiated hBMDS cells from each of the 10 donors and the cloned cell line were stained with either fluorescein isothiocyanate-conjugated (FITC) or phycoerythrin-conjugated (PE) antibodies (Becton Dickinson) against cell surface antigens [22] to obtain the phenotype of hBMDS cells. The data were analyzed with FCS express 2 software (DeNovo software, Ontario, Canada). Controls utilized FITC- and PE-conjugated isotype-matched immunoglobulins. Samples were analyzed in triplicate with data on $3 \times 10^4$ cells acquired per run.

**Testing stem cell properties**

The hBMDS cells were induced in vitro to test the ability of differentiation into endothelial cells by culturing the cells in medium containing 10 ng/ml VEGF for 14 days. The endothelial cell phenotype was examined by detecting surface expression of various vascular antigens including CD31 and von Willebrand factor (DAKO Corporation) [22, 23].

**Differentiation cultures**

To induce hBMDS cells to undergo pancreatic endocrine cell differentiation, the cloned cells were cultured in basic RPMI 1640 medium with the addition of 17.5 mM glucose and 10% FCS for two to four months. To further expand and promote cellular differentiation, the cells were cultured in basic medium plus three growth factors including 1 ng/ml FGF, 10 ng/ml EGF, and 10 ng/ml HGF for an additional two months. To promote cellular maturation, the cells were cultured for five days in RPMI 1640 medium with a low glucose concentration (5.5 mM), a lower concentration of FCS (5%), plus nicotinamide (10 mM) and exendin 4 (10 nM). The low glucose and low FCS medium without growth factors was necessary for inhibiting cell proliferation and promoting cell differentiation and maturation to increase the sensitivity to glucose stimulation.

**RT-PCR**

Total RNA was prepared from BMDS cell cultures at various stages, including low-glucose culture, and four- and twelve-weeks of high-glucose cultures using TRIzol reagent. Transcriptional gene expression related to pancreatic organogenesis from these cultures was determined by RT-PCR according to a published protocol [24] with minor modifications. The forward and reverse primers of each PCR set were designed to be located in different exons based on sequences obtained from GenBank (Table 1). PCR products were separated by electrophoresis in 2.5% agarose gel and the sequence of each PCR product confirmed by DNA sequence analysis.

**Immunocytochemistry and immunofluorescence**

Cytospin slides from D-hBMDS cells were prepared, air-dried, and kept frozen at -70°C until assay for insulin and C-peptide. Immunocytochemistry was performed with polyclonal guinea pig anti-insulin (1:500) and rabbit anti-rat-C-peptide antibody (1:200) as previously described [19]. After washing three times, the cells were incubated with Cy3-coupled secondary antibodies (1:1000) for 30 min. Guinea pig or rabbit serum was used as a negative control.

**Human insulin ELISA**

D-hBMDS cells were cultured in the presence or absence of 10-mM nicotinamide, or exendin 4, or both for five days in RPMI 1640 containing 5% FBS, and 5.5 mM glucose after the cells were confirmed to express insulin genes by RT-PCR. The cells were switched to serum-free medium containing 0.5% BSA for 12 hrs, washed twice with PBS, then stimulated by the addition of 17.5 mM additional glucose (final concentration of 23 mM) for various times. The culture media were collected and frozen at -70°C until assay for insulin release (in triplicate). The serum-free culture medium containing 0.5% BSA was used as a control for secreted insulin measurements. Insulin release was detected by using
human insulin ELISA kit (ALPCO Diagnostics, Windham, NH) with sensitivity of 0.15 μU/ml following the manufacturer’s protocols. This assay does not detect proinsulin.

**Deconvolution microscopy**

Cells were stained with Cy3-conjugated secondary antibodies after incubation with antibodies specific for insulin or C-peptide. The nuclei were counter-stained with DAPI and the cells were subjected to analysis using Delta Vision/Olympus OMT deconvolution microscopy. The images depict 3-dimensional projections of 25 optical slices (0.2 micron each) through the cell, centered focused on the DAPI stained chromatin in the nuclei. All images were scale-matched isotype antibody conjugates serving as negative control.

**Transplantation studies**

NOD-SCID mice (Jackson Laboratories) received five intraperitoneal injections of streptozotocin (STZ) (50 μg/g body weight) every day, according to our previously published procedures [19, 25] with minor modifications. The blood glucose levels were monitored using a One-Touch Profile blood glucose monitoring system (LifeScan Inc., Milpitas, CA). Within 12 days after the last injection, all mice became hyperglycemic with blood glucose levels >350mg/dl. D-hBMDS cells (2x10⁶/mouse) were then transplanted into the locations of both left renal subcapsular space and the distal tip of the spleen of the mice (n=6). Six control mice received sham surgery injected with the same amount of culture medium. Blood glucose levels were monitored in the afternoon between 16:00 to 18:00 hours every three days following transplantation without food deprivation. Two of the six implanted mice underwent splenectomy and nephrectomy to assess metabolic activity of the transplanted cells. The remaining mice were terminated at day 56 post-transplantation. The pancreatic tissues were harvested for analysis of residual beta cells.

**Bisulfite modification and methylation-specific PCR (MSP) of the p16 and p21 gene**

Sample DNA (1 μg) was modified with sodium bisulfite, converting all unmethylated but not methylated cytosine to uracil followed by amplification with primers specific for methylated versus unmethylated DNA. Methylation of 5-CpG islands in the promoters of tumor suppressor p16 and p21 genes was analyzed by MSP as described by Harmann JG et al [26] using a DNA methylation Kit (ZYMO Research, CA). Methylated primer for p16 is (150 bp): 5'-TTATTAGAGGGTGGGGCGGATCGC-3' and reverse, 5'-GACCCCGAACCGCGACCGTAA-3'; Unmethylated primer for p16 is (161 bp): 5'-TTATTAGAGGGTGGGGTGGATTGT-3' and reverse, 5'-CAACCCCAAACCACAACCATAA-3'; Methylated for p21 is (133bp): 5'-TACGCGAGGTTTCGGGAAGCGG-3' and 5'-AAAAACGACCCGCGCTCGGAGA-3'; Unmethylated for p21 is (142bp): 5'-TATGTGAGGTTCCGGGTCCTCTGC-3'.

---

**Table 1. Primer utilized for detection of pancreatic genes.**

<table>
<thead>
<tr>
<th>Gene</th>
<th>Forward Primer</th>
<th>Reverse Primer</th>
<th>Size</th>
<th>GenBank #</th>
</tr>
</thead>
<tbody>
<tr>
<td>Actin</td>
<td>gcctggggccctccccagggacca</td>
<td>cctcttaatgtacgcagatttc</td>
<td>540bp</td>
<td>NM_001101</td>
</tr>
<tr>
<td>Pdx-1</td>
<td>cccctgctagtaagcttacct</td>
<td>gcctctcctttttcaccc</td>
<td>262bp</td>
<td>NM_000209</td>
</tr>
<tr>
<td>Ngn-3</td>
<td>aagacgcagttggcactttaggc</td>
<td>cgtcagaagtcgtggtgc</td>
<td>229bp</td>
<td>NM_002099</td>
</tr>
<tr>
<td>NeuroD</td>
<td>ttgctctagtttccgaccagag</td>
<td>gctccagcgctgcgccttgag</td>
<td>688bp</td>
<td>NM_002500</td>
</tr>
<tr>
<td>Nkx2.2</td>
<td>aaccagtctgcgtacaccacaaagag</td>
<td>tcctcctgacgaggttctctgga</td>
<td>553bp</td>
<td>NM_002509</td>
</tr>
<tr>
<td>Nkx6.1</td>
<td>agagagtctagttcagctctgttg</td>
<td>actgctcttcaaacagctgcg</td>
<td>215bp</td>
<td>NM_000168</td>
</tr>
<tr>
<td>Islet-1</td>
<td>cgctgtgtttccctcttg</td>
<td>ttcttgctgagcagctgctg</td>
<td>233bp</td>
<td>NM_002202</td>
</tr>
<tr>
<td>Pax6</td>
<td>tcagacaccagtgtctacaccaaa</td>
<td>atcataacctcggctacctgcca</td>
<td>239bp</td>
<td>NM_000280</td>
</tr>
<tr>
<td>IAPP</td>
<td>atatactccgcttaccaagct</td>
<td>gagagagccccatattctgctcc</td>
<td>362bp</td>
<td>NM_000415</td>
</tr>
<tr>
<td>GK (Pancreas)</td>
<td>aagaggactgtctgggcactgt</td>
<td>tcagcagtgcggctgctaggg</td>
<td>572bp</td>
<td>NM_000162</td>
</tr>
<tr>
<td>Insulin</td>
<td>cgctctagcagaaaggcctcagcg</td>
<td>gcttataatctcttctctgcc</td>
<td>438bp</td>
<td>NM_000207</td>
</tr>
<tr>
<td>Glucagon</td>
<td>tgttgtctacagccacacttgctag</td>
<td>ctgttcctcttgttatcttc</td>
<td>287</td>
<td>NM_002054</td>
</tr>
<tr>
<td>PP</td>
<td>cgctgtctgtcttgtctctgtctcgttg</td>
<td>ccctcgaagccagccagcctctgcltcc</td>
<td>207</td>
<td>NM_002722</td>
</tr>
<tr>
<td>Somatostatin</td>
<td>cgctgatctgttcgagagctgtcgtg</td>
<td>cctagccggtgtttgatttaggcaagctc</td>
<td>196</td>
<td>NM_001048</td>
</tr>
</tbody>
</table>

* All PCR performed with 35 Cycles.
Insulin-producing cells from bone marrow-derived stem cells

TTGGGATTGG-3 and 5-AAAAACAACCCACACTCA ACC-3. DNA-PCR amplification conditions were an initial denaturation at 95°C for 10 min followed by 35 cycles of 45 seconds each at 95°C, 60°C, and 72°C, and a final extension at 72°C for 7 min. PCR products were analyzed on 3% agarose gels.

Results

Isolation of hBMDS cells

Human BM cells from healthy donors were used to obtain hBMDS cells. Adherent hBMDS cells were derived from cultures of unsorted BM mononuclear cells. The unattached cells were removed after 48-hours of culture, and rare adherent cells (Figure 1A-1) were cultured for an additional two weeks until the spindle-shaped adherent cells reached 70-80% confluence (Figure 1A-2, 3, 4). The cells were then released from the surface with trypsin-EDTA, re-plated, and expanded at a 1:3 dilution under the same culture conditions for several passages. A single cell derived cell clone (Figure 1A-5) was obtained by trypsinization of a single cell.
derived cell cluster with a cloning cylinder. The single cell derived cells as well as the mixed hBMDS cells were then immunophenotypically characterized.

Characterization of the hBMDS cells

The hBMDS cells were enumerated at each passage utilizing a hemocytometer. After three to four passages, the cells were labeled with FITC-, PE-, or Per-CPCoupled antibodies against CD45, CD34, CD117, CD38, CD64, CD14, CD13, CD33, CD11b, CD56, CD44, CD90, CD49b, CD19, CD20, CD2, CD5, CD4, CD8, CD3, CD7, HLA-DR, Class I HLA, and β2 microglobulin. Isotype-matched immunoglobulin served as control antibodies. Cells were analyzed using a FACS and prototypic results are presented in Figure 1B. The phenotype of cultured mixed and cloned hBMDS cells were identical; both were negative for leukocyte common antigen CD45, hematopoietic stem cell markers (CD34, CD38, and CD117), monocytic markers (CD64 and CD14), myeloid lineage markers (CD33, CD11b), a nature killer cell marker (CD56), T-cell markers (CD2, CD5, CD3, CD5, CD4, CD3, and CD7), and B-lymphocyte markers (CD19, and CD20). These cells also do not express class II HLA-DR. However the cells weakly expressed CD49b and CD44, and strongly expressed CD90, CD13, beta-2-microglobulin and class I HLA (Figure 1B). Thus, the morphology and phenotype were similar between early and late passages. The hBMDS cell phenotype was similar to that of human BM mesenchymal stem cells. These cells have the capacity of cell renewal and differentiation into endothelial-like cells after 14 days of incubation with VEGF (data not shown), demonstrating stem cell like properties. The cells were stored in liquid nitrogen and, when re-started, the morphology and immunophenotype remained unchanged.

In vitro differentiation of hBMDS cells

To induce cell differentiation, the cloned hBMDS cells (Figure 2A) were switched into RPMI 1640 medium containing 10% FCS, high glucose (23mM), and with or without various growth factors as described in the Methods section. After two to four months of in vitro induction, the cells began to form three-dimensional clusters (Figure 2B) similar to that shown in our previous study [24]. To promote maturation of the precursors of BM-derived pancreatic endocrine cells, the cells were switched to the medium containing 5% FCS with 10mM nicotinamide, exendin 4, and low concentration of glucose (5.5 mM) after the expansion of the differentiated cells. This step facilitated cluster formations (Figure 2C) both in number and mass with increased the sensitivity of glucose responsiveness. The cell differentiation was monitored by RT-PCR for islet-related gene expression and glucose-responsive insulin secretion (see below).

Gene expression of hBMDS cells and D-hBMDS cells

To determine if the islet-like clusters appearing in the hBMDS cell cultures had differentiated to endocrine-hormone expressing cells, the gene expression of endocrine cell differentiation markers and hormones was measured using RT-PCR at various stages of in-vitro high-glucose differentiation. Undifferentiated hBMDS cells, cultured under low glucose conditions, ex-
pressed no detectable levels of any of the tested pancreatic transcription factors (Figure 3, lane 1). In contrast, the 4-week high-glucose D-hBMDS cells expressed Pdx1, Isl-1, and Ngn 3 genes (Figure 3, lane 2). The Ngn3 gene exhibited transient expression at four-weeks of high-glucose culture but was undetectable at 12-weeks of high-glucose culture, which is consistent with its expressing pattern during developing pancreas [27]. In contrast, NeuroD, Pax4, IAPP, and insulin genes were activated at 12-weeks of high-glucose differentiation, along with persistently increasing expression of Pdx1 and Isl-1 genes (Figure 3, lane 3). No detectable gene expression of Nkx6.1, Pax6, and GK, as well as other pancreatic hormones including glucagon, pancreatic polypeptide, and somatostatin were observed, which is consistent with pancreatic precursor-like cells at the tested stages. Total RNA from human islets expressed all of the expected islet-related genes (Figure 3, lane 4). The negative control showed no DNA contamination (Figure 3, lane 5). These results indicated that the hBMDS cells, under in-vitro high-glucose induction, transdifferentiated into cells exhibiting a genotypic expression profile similar to pancreatic beta-like cells.

**Synthesis and process of insulin by D-hBMDS cells**

To determine if the D-hBMDS cells actually synthesize and process insulin after the continued cell differentiation and maturation, the cells were evaluated for insulin and C-peptide expression by immunofluorescence (Figure 4). There was a marked increase in the percentage of the IPC that represent approximately 20% of examined cells, with strong cytoplasmic staining for insulin (Figure 4A left-middle) and C-peptide (Figure 4A left bottom). INS-1 cells were used as a positive control for insulin and C-peptide immunostaining. These results indicate that the D-hBMDS cells can be further induced in vitro to differentiate into more mature IPC. To examine the distribution of insulin granules, we used deconvolution microscopy to visualize the insulin granule and C-peptide distribution in the in-vitro-D-hBMDS cells and compare with INS-1 insulinoma cells. Figure 4B shows the distribution of intracellular insulin and C-peptide. Interestingly, the insulin granules in the differentiated cells were arranged in a polarized fashion, with most of the granules being situated within one side of the cell similar to the location in INS-1 cells. This pattern is consistent with insulin being released in a physiologic response to glucose stimulation.

**Insulin release in response to glucose stimulation**

To determine whether the differentiated cells are responsive to a glucose challenge, the time-course of insulin release from the D-hBMDS cells with various culture conditions was measured. In order to increase the sensitivity of the cells to a high-glucose challenge, the cells were switched to low serum, low-glucose medium plus either exendin 4, nicotinamide, or both for five days. The cells then were switched to serum-free low-glucose medium containing 0.5% BSA overnight, then stimulated by the addition of 23 mM glucose for various times up to eight hours.
Insulin-producing cells from bone marrow-derived stem cells

As demonstrated in Figure 5A, the peak of insulin release occurred at two hours after the glucose challenge in the culture condition of pretreatment with exendin 4. Interestingly, insulin release in cells pretreated with both nicotinamide and exendin 4 occurred much earlier and peaked within a few minutes in response to a glucose challenge and returned to a lower level at one hr (Figure 5B). Moreover, the intensity of insulin release after pretreatment with both nicotinamide and exendin 4 was much stronger than after exendin 4 treatment alone. Surprisingly, there was no detectable insulin release when the cells were treated with nicotinamide alone. These results demonstrated that the D-hBMDS cells are functional IPC capable of releasing insulin in response to a glucose challenge.

Amelioration of hyperglycemia in NOD-SCID mice

To determine if the D-hBMDS cells were able to reduce blood glucose levels in STZ-induced hyperglycemic NOD-SCID mice, animals were transplanted with or without the D-hBMDS cells. Approximately one week following transplantation, glucose levels in D-hBMDS cell-transplanted mice were reduced by almost one-half (p<0.01, Figure 6). However, blood glucose levels were not completely normalized (i.e., eu-glycemia). These data suggest that even though the numbers of implanted cells were sufficient to maintain blood glucose reduction over the entire monitoring period, it may not have been enough for a complete reversal of hyperglycemia. By comparison, control mice did not exhibit any decrease in blood glucose levels. When two mice from the transplant group underwent surgery to remove implants, both were observed to have a rapid increase in blood glucose levels (>350mg/dl after 24hr post surgery), suggesting that the transplanted cells were responsible for the reduction in blood glucose levels. Post-mortem examination of the pancreas of all mice demonstrated few scattered residual insulin-positive cells, yet no significant differences were observed between pancreata of control and implanted mice (data not shown). This observation suggests that the STZ treatment of mice used in this study eliminates a majority of pancreatic beta cells and the residual beta cells...
Insulin-producing cells from bone marrow-derived stem cells

were insufficient for maintaining normal glucose levels.

At 40 to 45 days post-transplantation, we noted that the remaining mice receiving D-hBMDS cells developed an enlarged tumor mass around the left renal region, palpable to touch. Furthermore, the blood glucose levels of these mice gradually rose to levels above 300 mg/dl. These animals were sacrificed between 45 to 56 days post-transplantation and the histology of the tumor examined. These studies showed the tumor cells had malignant cell morphology with an infiltrating border adjacent to normal renal tissue and the frequent presence of atypical mitosis. These findings suggested that the transplanted D-hBMDS cells likely represented a mixture of differentiated and undifferentiated cells, capable of either reducing hyperglycemia or formation of a tumor mass, respectively.

Hypermethylation of p16 and p21 promoter region in transformed hBMDS cells

The in vivo data from these animal studies prompted us to further study the nature of our hBMDS cell line. Since aberrations in the DNA methylation patterns are recognized as a hallmark of the cancer cell, and silencing of tumor suppressor genes such as p16 and p21 has established promoter hypermethylation serve as a common mechanism for tumor suppressor inactivation in human cancer [28, 29]. Using sensitive methylation-specific PCR (MSP), we examined the methylation status of the tumor suppressor gene p16 and p21 using sodium bisulfite-treatment of DNA. Specifically, the CpG island methylation in p16 and p21 were examined by MSP in early passage hBMDS cells as well as the clonal line from hBMDS cells. A human multiple myeloma-derived cell line (H929) and normal human DNA is served as controls. Hypermethylation of p16 and p21 promoter
Insulin-producing cells from bone marrow-derived stem cells

Figure 7. Hypermethylation of \( p16 \) and \( p21 \) tumor suppressor genes in cloned hBMDS cells. Viewed from left to right, four samples are as following sequence: primary human BMDS cells (P-BMDS), cloned hBMDS cells (T-BMDS), human tumor cell line (H929), and normal human lymphocytes (normal). In the \( p16 \), and \( p21 \) promoter regions, the DNA PCR products showed hypermethylated (M) in T-BMDS, whereas the PCR products from P-BMDS were unmethylated (U). Human tumor cell line H929 serves as a positive control for hypermethylated DNA (M), normal lymphocyte DNA as a negative control for unmethylated DNA (U). Expression of house-keeping actin gene serves as sample DNA quality control.

To overcome this latter limitation, we explored the possibility of using hBMDS cells as sources for transdifferentiation into IPC under specific \textit{in-vitro} culture conditions. Bone marrow has been known for years to represent a safe and abundant source for large quantities of adult stem cells. In the present study, we isolated, cloned, and characterized the immunophenotype of hBMDS cells. We also generated IPC from hBMDS cells using \textit{in vitro} differentiation procedures, with RT-PCR, and immunofluorescence confirming the presence of insulin synthesis and process in the cells. Determination of insulin release, in response to increased glucose concentration in cells cultured with different maturation factors, demonstrated that insulin was released in a time dependent fashion. Moreover, the release of insulin occurred earlier in more mature cells than less mature cells. We believe that this pattern mimics the physiological release of insulin by native pancreatic beta cells. Our study provides direct evidence that human bone marrow contains pluripotent cells capable of being reprogrammed \textit{in vitro} to become IPC. These cells demonstrate the ability to respond to the glucose challenge to release insulin and reduce blood glucose levels in diabetic mice. This finding has also been confirmed by several other studies, demonstrating that BM-derived stem cells can be induced to transdifferentiate into insulin-releasing cells using \textit{in vitro} system [19, 20].

A study by Ianus et al [15] also provides \textit{in vivo} evidence of adult mouse BM harboring cells that can transdifferentiate into glucose-competent pancreatic endocrine cells. The results of that study suggested that the \textit{in vivo} generation of IPC is likely due to transdifferentiation of BMDS cells into beta cells rather than of cell fusion. Kojima, et al surprisingly observed that proinsulin- and insulin-positive cells could be detected in the multiple organs including liver, adipose tissue, spleen, bone marrow, and thymus in hyperglycemic mice or rats and further bone marrow transplantation experiments showed that most of the extrapancreatic proinsulin-producing cells originated from the bone marrow [16]. In contrast, two recent studies [17, 18] showed that there is little evidence of transdifferentiation of BM-derived cells into pancreatic beta cells in the chemically induced diabetic mice. A current unresolved issue in terms of the plasticity of BMDS cells in \textit{in-vivo} animal studies is transdifferentiation versus cell fusion.

Discussion

Recent studies have demonstrated the feasibility of generating IPC from progenitor cells of various sources including pancreas [30, 31], liver [24], intestinal epithelium [32], and pluripotent embryonic stem cells of mouse [33, 34] and human [35] origin. However, even with the conceptual advance offered by these findings, some obstacles, such as immune rejection and autoimmunity against newly formed beta cells from pancreatic stem cells, remain. Furthermore, it may prove very difficult to obtain enough autologous adult stem cells from these organs.
Insulin-producing cells from bone marrow-derived stem cells

as an underlying mechanism for adult stem cell plasticity. In our current study as well as other in vitro studies [19, 20], since homogeneous hBMDS cells were used to induce in vitro differentiation into IPC, cell fusion is clearly not the explanation for the presence of competent IPC although a few binucleated cells were observed in the culture dishes.

To confirm that we have generated IPC from hBMDS cells which may have features of pancreatic islet beta-like cells, we determined the following islet cell characteristics: 1) expression of otherwise silent islet cell differentiation transcription factors including Isl-1, Ngn 3, Pdx-1, NeuroD, Pax4, IAPP, and insulin by RT-PCR; 2) presence of C-peptide (by-product of de novo insulin synthesis) and insulin detected by immunofluorescence; 3) insulin and C-peptide release as determined by deconvolution microscopy; 4) glucose stimulated time-dependent insulin release; and 5) reduction of hyperglycemia in diabetic mice. Rajapogal et al. reported that false-positive insulin-producing human embryonic stem cells did not stain with an antibody for C-peptide, and did not contain transcripts for insulin mRNA. In contrast, our transdifferentiated IPC possessed these islet cell traits including the presence of C-peptide and insulin. The identified islet-like cells contained transcripts for the insulin gene along with Isl-1, Pdx-1, NeuroD, Pax4, and IAPP and they also contained insulin and C-peptide. In addition, the islet-like cells exhibited a time-dependent rapid insulin release (Figure 5) that closely matched the response of native islet cells to a glucose challenge. Finally, in our study, insulin release did not involve absorbed insulin, since the culture medium did not contain insulin. Thus, our data clearly demonstrate the ability of hBMDS cells to differentiate into IPC that have many characteristics of pancreatic beta-cells.

There are two key steps in our cell culture conditions that appear to be critical for inducing differentiation of hBMDS cells into insulin-producing islet-like cells. First, the hBMDS cells initially need to be cultured in medium containing a high-glucose concentration (23mM) for various durations of time until certain genes such as islet-1, Ngn3, Pdx1, NeuroD, and insulin become detectable. Second, the transdifferentiated hBMDS cells require subsequent culture with maturation factors, such as exendin-4 and nicotinamide, in a medium containing low FCS and low glucose, in order to promote cell maturation and to restore the sensitivity to a glucose challenge. Exendin-4 is a potent glucagon-like peptide-1 (GLP-1) agonist that has previously been shown to stimulate both beta cell replication and neogenesis from ductal progenitor cells [36], GLP-1 stimulates insulin secretion and augments beta cell mass via activation of beta cell proliferation and islet neogenesis [37]. Nicotinamide is a potent activator of beta cell regeneration [38] and it promotes liver stem cell in vitro transdifferentiation and maturation into insulin-producing cells [24]. Our protocol of transdifferentiation employed two different cellular factors in addition to high-glucose conditions to convert hBMDS cells into IPC. We demonstrated that exendin-4 treatment alone of the hBMDS cells was not capable of producing a rapid glucose-stimulated response, whereas exendin-4 plus nicotinamide treatment of hBMDS cells resulted in an islet-like glucose-stimulated instantaneous insulin secretion (Figure 5). This suggests that multiple pathways of islet-cell differentiation must be induced for complete maturation and development of islet-like cells from hBMDS cells. For example, exendin-4 treatment of hBMDS cells may result in upregulation of islet cell differentiation factors. However, exendin-4 may be necessary but not sufficient for complete islet-like cellular differentiation. Whereas, in the presence of both exendin-4 and nicotinamide, this may induce upregulation of required co-factors of islet cell differentiation that allow for sufficient transdifferentiation of islet-like cells.

Since there are multifactorial influences in the transdifferentiation of hBMDS cells into competent IPC, many questions are left unanswered and unresolved issues do remain. For example, how much BM is required to generate a sufficient amount of islet-like cells in a cell based therapy for type 1 diabetes? What is the expansion capacity of the D-hBMDS cells? Does the patient’s age affect the quality of the hBMDS cells? Is there genetic predisposition affecting the process of in vitro transdifferentiation? In this study, for the purpose of reproducibility of our results, we used the clonal hBMDS cell line derived from a 10-year-old patient without type 1 diabetes and with no genetic manipulation in order to explore the feasibility of generating IPC in vitro. Although development of clonal expandable hBMDS cell line is a useful tool for study the mechanism and conditions for cell transdifferentiation, we also noticed from our data that one of the disadvantages for a long-term in vitro
manipulation is the potential for spontaneous cell transformation. This adverse effect has also been observed recently by other groups during in vitro long-term culture of both mouse and human mesenchymal stem cell [39-41]. Therefore, it raises concern in terms of clinical applications that BMDS cells should not be manipulated in vitro for long time in order to prevent from possible cell spontaneous malignant transformation. Therefore, it is still a remaining and arduous task to find the decisive steps (e.g., addition of exogenous factors) and shortest time for in-vitro for the transdifferentiation without potential for neoplastic transformation.

In our experience, the differentiated cells are different from beta cell-derived cell lines such as β-TC and INS-1 cells in terms of gene expression profile, cell maturity, and capacity of processing and release of insulin in response to glucose stimulation. Hence, one can also question whether these cells can really be pushed to the level of maturity like true beta cells by changing the in vitro culture conditions. Another relevant clinical question concerning the issue of autoimmunity is whether the immune response to beta cell antigens will result in recognition and destruction of the newly generated insulin-producing cells derived from hBMDS cells. While further research is obviously required to settle these important issues, the results presented here lend a sense of optimism to the notion that transdifferentiation of stem cells to insulin-producing cells may represent a viable therapeutic option for type 1 diabetes as well as caution for further clinical applications.

Acknowledgement

We thank Dr. Xiao-Ping Deng for providing human islet RNA for RT-PCR positive controls and Dr. Christopher B. Newgard for his generous gift of INS-1 cell line (cloneB32/13). This work was supported by grants R21-DK063270, KO8-DK064054, and DK071831 (to Yang LJ) from the National Institutes of Health; and Florida Bankhead-Coley Research Grant (to Yang LJ).

Address correspondence to: Dr. Li-Jun Yang, 1600 SW Archer Road, P.O. Box 100275, Gainesville, FL 32610 USA Tel: (352) 392-0005; Fax: (352) 392-3053; E-mail: yanglj@pathology.ufl.edu

Reference

[13] Wei Y, Chen YH, Li LY, Lang J, Yeh SP, Shi B,
Insulin-producing cells from bone marrow-derived stem cells


[38] Akiyama T, Takasawa S, Nata K, Kobayashi S,
Insulin-producing cells from bone marrow-derived stem cells


